During the quarter, the plant and cannabinoid business, including sales of Holi Hemp and Hyalolex-branded products, accounted for 20% of the company's revenue.
The remaining 80% of the revenue came from the company’s India-based infrastructure operations, India Globalization Capital said in a press release.
The company disclosed a net loss for the quarter of $1.32 million, or 3 cents per share, versus a loss of $1.19 million and 3 cents per share in the corresponding quarter in the previous year.
The bigger loss was mostly due to raised plant costs and cannabinoid business and legal expenses, according to the company.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
India Globalization Capital disclosed operational updates that occurred during the quarter, such as obtaining Puerto Rico Institutional Review Board approval for its pharmaceutical trial for Hyalolex; reaching more dispensaries in Puerto Rico for Hyalolex sales; and opening a new research and marketing hub in Bogota.
India Globalization Capital is a Maryland-based company that runs two operations: plant and cannabinoid-based products and infrastructure.
The stock was trading 2.57% higher at 94 cents in Wednesday's premarket session.
India Globalization Capital Subsidiary Secures Hemp Cultivation, Harvesting License In Arizona
The Week In Cannabis: Colorado Hits B In Sales, Harborside In Canada, Kroger Embraces CBD, And More
See more from Benzinga
- New CBD Service, Colette, Aims To Help Women 'Define Their Own Ways To Shine'
- Willow Biosciences To Trade On The OTCQB Venture Market
- 'Best Use Of The Company's Balance Sheet': Terra Tech, OneQor Pharmaceutical To Merge
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.